Kistler-Tiffany Companies’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $1.69M | Buy |
12,580
+266
| +2% | +$39K | 0.28% | 69 |
|
|
2023
Q1 | $1.96M | Buy |
12,314
+70
| +0.6% | +$10.7K | 0.37% | 56 |
|
|
2022
Q4 | $1.98M | Sell |
12,244
-675
| -5% | -$104K | 0.41% | 51 |
|
|
2022
Q3 | $1.73M | Buy |
12,919
+3
| +0% | +$430 | 0.39% | 47 |
|
|
2022
Q2 | $1.98M | Sell |
12,916
-145
| -1% | -$22.2K | 0.43% | 41 |
|
|
2022
Q1 | $2.12M | Buy |
13,061
+163
| +1% | +$23.7K | 0.4% | 47 |
|
|
2021
Q4 | $1.75M | Buy |
12,898
+183
| +1% | +$21.6K | 0.34% | 50 |
|
|
2021
Q3 | $1.37M | Buy |
12,715
+452
| +4% | +$51.6K | 0.31% | 55 |
|
|
2021
Q2 | $1.38M | Buy |
12,263
+1,305
| +12% | +$147K | 0.32% | 56 |
|
|
2021
Q1 | $1.19M | Buy |
10,958
+751
| +7% | +$80.3K | 0.31% | 58 |
|
|
2020
Q4 | $1.09M | Buy |
10,207
+706
| +7% | +$67.8K | 0.31% | 53 |
|
|
2020
Q3 | $832K | Sell |
9,501
-659
| -6% | -$62K | 0.27% | 64 |
|
|
2020
Q2 | $997K | Buy |
10,160
+1,768
| +21% | +$156K | 0.35% | 52 |
|
|
2020
Q1 | $743K | Hold |
8,392
| – | – | 0.26% | 57 |
|
|
2019
Q4 | $743K | Sell |
8,392
-197
| -2% | -$16.4K | 0.26% | 58 |
|
|
2019
Q3 | $650K | Buy |
8,589
+373
| +5% | +$25.6K | 0.25% | 59 |
|
|
2019
Q2 | $597K | Buy |
8,216
+459
| +6% | +$36.1K | 0.23% | 67 |
|
|
2019
Q1 | $625K | Buy |
7,757
+640
| +9% | +$52.4K | 0.26% | 62 |
|
|
2018
Q4 | $656K | Sell |
7,117
-168
| -2% | -$14.8K | 0.31% | 53 |
|
|
2018
Q3 | $689K | Buy |
7,285
+107
| +1% | +$10.1K | 0.28% | 60 |
|
|
2018
Q2 | $665K | Sell |
7,178
-18
| -0.3% | -$1.76K | 0.29% | 59 |
|
|
2018
Q1 | $681K | Sell |
7,196
-130
| -2% | -$14.3K | 0.28% | 67 |
|
|
2017
Q4 | $708K | Buy |
7,326
+5
| +0.1% | +$471 | 0.28% | 62 |
|
|
2017
Q3 | $651K | Sell |
7,321
-18
| -0.2% | -$1.37K | 0.27% | 66 |
|
|
2017
Q2 | $532K | Sell |
7,339
-1,007
| -12% | -$67.7K | 0.24% | 70 |
|
|
2017
Q1 | $544K | Buy |
8,346
+186
| +2% | +$11.7K | 0.26% | 64 |
|
|
2016
Q4 | $511K | Sell |
8,160
-198
| -2% | -$12.1K | 0.25% | 63 |
|
|
2016
Q3 | $527K | Sell |
8,358
-246
| -3% | -$15.9K | 0.26% | 63 |
|
|
2016
Q2 | $533K | Buy |
8,604
+5
| +0.1% | +$305 | 0.27% | 57 |
|
|
2016
Q1 | $491K | Sell |
8,599
-119
| -1% | -$6.63K | 0.27% | 58 |
|
|
2015
Q4 | $516K | Buy |
8,718
+861
| +11% | +$49.6K | 0.28% | 60 |
|
|
2015
Q3 | $427K | Buy |
7,857
+417
| +6% | +$27.1K | 0.26% | 67 |
|
|
2015
Q2 | $500K | Buy |
7,440
+188
| +3% | +$12.3K | 0.3% | 60 |
|
|
2015
Q1 | $425K | Sell |
7,252
-96
| -1% | -$5.8K | 0.27% | 66 |
|
|
2014
Q4 | $481K | Buy |
7,348
+3
| +0% | +$189 | 0.31% | 57 |
|
|
2014
Q3 | $424K | Hold |
7,345
| – | – | 0.28% | 62 |
|
|
2014
Q2 | $415K | Sell |
7,345
-200
| -3% | -$10.5K | 0.3% | 63 |
|
|
2014
Q1 | $388K | Sell |
7,545
-231
| -3% | -$11.7K | 0.29% | 65 |
|
|
2013
Q4 | $411K | Buy |
7,776
+142
| +2% | +$6.98K | 0.31% | 65 |
|
|
2013
Q3 | $341K | Buy |
7,634
+1
| +0% | +$44 | 0.28% | 69 |
|
|
2013
Q2 | $316K | Buy |
+7,633
| New | +$334K | 0.27% | 68 |
|
Other funds holding ABBV
Kistler-Tiffany Companies's ABBV Position: Q2 2023 in Review
Kistler-Tiffany Companies increased its AbbVie (ABBV) stake by 2.2% in Q2 2023, buying an estimated $39K and bringing the position to 12,580 shares worth $1.69M. The position accounts for 0.28% of the portfolio, ranked #69.
Kistler-Tiffany Companies first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $2.12M in Q1 2022. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.
- Kistler-Tiffany Companies held 12,580 shares of AbbVie worth $1.69M as of Q2 2023.
- Kistler-Tiffany Companies bought 266 AbbVie shares in Q2 2023, an estimated $39K.
- AbbVie made up 0.28% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #69 holding.
- Kistler-Tiffany Companies first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
- Kistler-Tiffany Companies's AbbVie position peaked at $2.12M in Q1 2022.
- 3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.
Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.